Sid Shenai's path to venture investing is unusual: he studied physics at Harvard, earned a JD/MBA, worked in behavioral-finance research, ran Bracebridge Capital's developed-market rates desk, and then co-founded and led Proof Diagnostics, where he licensed STOPCovid from the Broad Institute and turned it into a portable testing device later valued by Ginkgo for its OMEGA enzyme libraries. He now invests in seed and Series A companies where AI meets life sciences, diagnostics, and medical devices, sits on the board of Terray Therapeutics, and serves as a translational research adviser at the University of Washington's Institute for Protein Design.